Intervention of FSP1 and expression in the early stage of atypical adenomatoid hyperplasia (AAH) to adenocarcinoma in situ (AIS) or to micro-infiltrating adenocarcinoma (MIA), and thus intervention in ferroptosis of tumor initiation, may be a novel therapeutic direction for KRAS-mutated LUAD (Figure 1). The gene discussed is AIFM2; the disease is neoplasm.